gw844520 and Malaria

gw844520 has been researched along with Malaria* in 2 studies

Other Studies

2 other study(ies) available for gw844520 and Malaria

ArticleYear
Quinolone-3-diarylethers: a new class of antimalarial drug.
    Science translational medicine, 2013, Mar-20, Volume: 5, Issue:177

    The goal for developing new antimalarial drugs is to find a molecule that can target multiple stages of the parasite's life cycle, thus impacting prevention, treatment, and transmission of the disease. The 4(1H)-quinolone-3-diarylethers are selective potent inhibitors of the parasite's mitochondrial cytochrome bc1 complex. These compounds are highly active against the human malaria parasites Plasmodium falciparum and Plasmodium vivax. They target both the liver and blood stages of the parasite as well as the forms that are crucial for disease transmission, that is, the gametocytes, the zygote, the ookinete, and the oocyst. Selected as a preclinical candidate, ELQ-300 has good oral bioavailability at efficacious doses in mice, is metabolically stable, and is highly active in blocking transmission in rodent models of malaria. Given its predicted low dose in patients and its predicted long half-life, ELQ-300 has potential as a new drug for the treatment, prevention, and, ultimately, eradication of human malaria.

    Topics: Animals; Antimalarials; Atovaquone; Drug Resistance; Drug Synergism; Life Cycle Stages; Malaria; Malaria, Falciparum; Mice; Plasmodium falciparum; Plasmodium vivax; Proguanil; Pyridones; Quinolones

2013
Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.
    Journal of medicinal chemistry, 2008, May-08, Volume: 51, Issue:9

    A series of diaryl ether substituted 4-pyridones have been identified as having potent antimalarial activity superior to that of chloroquine against Plasmodium falciparum in vitro and murine Plasmodium yoelii in vivo. These were derived from the anticoccidial drug clopidol through a systematic study of the effects of varying the side chain on activity. Relative to clopidol the most active compounds show >500-fold improvement in IC50 for inhibition of P. falciparum in vitro and about 100-fold improvement with respect to ED50 against P. yoelii in mice. These compounds have been shown elsewhere to act selectively by inhibition of mitochondrial electron transport at the cytochrome bc1 complex.

    Topics: Animals; Antimalarials; Malaria; Mice; Parasitic Sensitivity Tests; Plasmodium falciparum; Plasmodium yoelii; Pyridones; Structure-Activity Relationship

2008